ReviewFrontiers in pediatrics2025
Neonatal brain MRI to prognosticate neurodevelopmental outcomes in fetal growth restricted infants: a systematic review.
Review in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurodevelopmental disorders in children: the role of MRI in early detection and intervention planning.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The purpose of this study was to identify magnetic resonance imaging (MRI) brain markers at birth that prognosticate neurodevelopmental outcomes at ≥12 months of age in fetal growth restricted (FGR) infants. Methods: A systematic literature search was undertaken in PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Scopus in March 2025. Articles were assessed by two reviewers. The inclusion criteria included papers relating to infants with birth weight <10th percentile, with assessed neurodevelopmental outcomes at 12 months of age or older, and MRI performed at birth with markers for neurodevelopment, and comparison of data to appropriate for gestational age (AGA) infants. The quality of studies was assessed using the Cochrane-approved Quality in Prognosis Studies tool. Results: Three articles met the inclusion criteria. All demonstrated a correlation between MRI in regions of the brain and neurodevelopmental outcomes >12 months of age across all studied infants. However, only one of the three studies correlated early MRI results with neurodevelopmental outcomes specifically in FGR infants and thus a meta-analysis could not be performed. The single study reports a positive correlation between MRI total parenchyma area and cognitive scores in FGR infants. Conclusion: The current literature highlights the developmental risk in FGR vs. AGA infants. FGR neonates have significantly different MRI results compared to AGA neonates and MRI findings in the neonate are associated with adverse neurodevelopmental outcomes. However, current evidence is insufficient to firmly establish MRI prognostic capabilities specifically for FGR infants. Sub-group analysis of the FGR cohort in the reported studies and the use of more advanced MRI techniques would likely elucidate this. Further research is required to ascertain robust clinical MRI markers of early adverse brain development in the FGR newborn. Systematic Review Registration: identifier CRD42023400436.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.